Table 3 PFS-related univariate and multivariate analysis in the training group

HR (95% CI)

p

HR (95% CI)

p

Gender (Male vs. Female)

0.685 (0.364–1.29)

0.241

Age (≤ 65 vs. >65)

0.853 (0.483–1.509)

0.586

KPS (≤ 80 vs. >80)

0.871 (0.501–1.513)

0.623

Smoking status (Never vs. Former/current)

1.231 (0.711–2.132)

0.458

Alcohol consumption (Never vs. Former/current)

1.674 (0.959–2.922)

0.070

Tumor location (Cervical reference)

0.294

 Upper thoracic

2.94 (0.396–21.828)

0.292

 Middle thoracic

3.321 (0.443–24.883)

0.243

 Lower thoracic

5.333 (0.67-42.442)

0.114

Clinical stage (II vs. III)

2.497 (0.988–6.307)

0.053

Radiation dose (>60 Gy reference)

0.246

 >50.4 Gy ≤ 60 Gy

0.768 (0.375–1.575)

0.471

 ≤50.4 Gy

1.374 (0.58–3.253)

0.470

Chemoradiotherapy (SCRT vs. CCRT)

0.596 (0.341–1.041)

0.069

Radiation therapy (3D-CRT vs. IMRT)

1.008 (0.499–2.035)

0.983

CHEK2 (Wild vs. Mutation)

2.658 (1.029–6.867)

0.044

NOTCH2 (Wild vs. Mutation)

1.77 (0.694–4.515)

0.232

HRR (Wild vs. Mutation)

2.671 (1.281–5.569)

0.009

2.747 (1.313–5.748)

0.007

Rad-score (≤ 0.36 vs. > 0.36)

2.016 (1.09–3.728)

0.025

2.052 (1.109–3.798)

0.022